Lisa Lowry-Rohlfing, MD
Family Medicine · Chester, ILNPI 1386755973
Payments from drug & device makers
Across 48 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$112
- Merck$85
- Novo Nordisk$78
- Dexcom, Inc.$64
- Boehringer Ingelheim$55
- Sanofi Pasteur Inc.$51
- plus $353 from 15 others
What the payments were for
- Food & beverage$798100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $112 |
| Merck | 4 | $85 |
| Novo Nordisk | 5 | $78 |
| Dexcom, Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $55 |
| Sanofi Pasteur Inc. | 2 | $51 |
| Astellas Pharma US Inc | 3 | $44 |
| AstraZeneca | 3 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Lundbeck LLC | 1 | $31 |
| Amgen | 2 | $30 |
| AbbVie | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Exact Sciences | 1 | $15 |
| GSK | 1 | $12 |
| Eisai Inc. | 1 | $11 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$798 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $108,742 |
| TrulicityDulaglutide | 48 | $76,184 |
| JardianceEmpagliflozin | 54 | $54,870 |
| FarxigaDapagliflozin Propanediol | 76 | $53,506 |
| GemtesaVibegron | 74 | $36,473 |
| OzempicSemaglutide | 33 | $34,694 |
| TradjentaLinagliptin | 47 | $32,226 |
| MounjaroTirzepatide | 24 | $24,724 |
| EntrestoSacubitril/Valsartan | 26 | $23,142 |
| XareltoRivaroxaban | 23 | $19,296 |
| MyrbetriqMirabegron | 37 | $17,206 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $17,167 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $17,043 |
| RexultiBrexpiprazole | 12 | $16,628 |
| JanuviaSitagliptin Phosphate | 15 | $15,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $16 | $114,341228 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $100,90872 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $55 | $99,992121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $39 | $60,82188 claims |
| GSKIncruse Ellipta, Anoro Ellipta, Breo Ellipta, Trelegy Ellipta, Shingrix | $12 | $60,062125 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $112 | $36,47374 claims |
| Novo NordiskOzempic | $78 | $34,69433 claims |
| MerckJanuvia, Belsomra | $85 | $22,53431 claims |
| Johnson & JohnsonXarelto | $15 | $19,29623 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $17,20637 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17 | $16,62812 claims |
| AbbVieLinzess | $29 | $14,14423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chester
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.